Pacira Cancels Q3 Earnings Release and Withdraws 2026 Guidance Pending Viatris Deal
PCRX sits 94% above its 52-week low of $18.8.
Summary
Pacira will skip its September 30, 2026 quarterly earnings release and call and has withdrawn its 2026 financial guidance while Viatris' $36.50-per-share all-cash tender offer is pending.
Key Events · M&A and Partnerships · PCRX
-
Q3 Earnings Release Cancelled
Citing the pending Viatris offer and merger, Pacira will not issue an earnings release for the quarterly period ended September 30, 2026 and will not hold a conference call.
-
2026 Guidance Withdrawn
The company is withdrawing its previously issued 2026 financial guidance and will not provide further updates during the pendency of the proposed Offer and Merger.
-
Viatris Tender Offer Running
Under the October 8, 2026 merger agreement, a Viatris subsidiary commenced a tender offer on October 30, 2026 to buy all outstanding shares for $36.50 per share in cash.
-
Deal Conditions Still Open
Completion remains subject to conditions including the Minimum Condition defined in the merger agreement and required regulatory approvals; no closing date is stated.
Analysis · PCRX · Life Sciences
With Viatris' $36.50-per-share all-cash tender offer running, Pacira is going dark on financial disclosure. There will be no Q3 earnings release or call, and the 2026 guidance issued earlier this year is withdrawn with no further updates until the deal closes. For shareholders, the practical effect is that the $36.50 cash price is now the only number that matters: quarterly results and guidance no longer drive the stock, and the remaining risk is deal completion (the minimum tender condition and regulatory approvals), not operating performance.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCRX was trading at $36.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.80 to $36.67. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.